2022 LUPUS MEETING - cloudfront.net
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
5-8 OCTOBER 2022 13th EUROPEAN LUPUS MEETING FINAL PROGRAMME
STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
ENDORSEMENTS
The meeting is endorsed by
2
STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
INDEX
Welcome message p. 3
SLEuro Executive Committee p. 4
Committees p. 5
Programme overview p. 6
Pre-Conference p. 11
Scientific programme p. 12
Wednesday 5 October p. 12
Thursday 6 Ocotber p. 13
Friday 7 October p. 21
Saturday 8 October p. 26
E-Posters p. 27
Scientific information p. 50
Abstract book p. 50
Congress app p. 50
Fishbowls p. 51
Guidelines for chairs and speakers p. 52
Oral communications and E-Poster information p. 52
General information p. 54
Congress venue p. 54
Floorplans p. 55
Registration information p. 61
Useful information p. 62
Sponsored sessions p. 65
Acknowledgements and industry support p. 74
3
STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
WELCOME
Dear Colleagues and Friends,
We have now finalized both the scientific and social programs for the 13th European
Lupus Meeting 2022, in Stockholm October 5-8. We are grateful for the enthusiastic
work by our colleagues and the AIM Group, which has made it possible to present an
exceptional program with outstanding speakers and many presentations by young
colleagues who are the future lupologists. We all long for an opportunity to meet
each other for lectures, seminars, symposia, poster sessions, discussions and debates,
activities with the aim of making us better equipped to encounter the many challenges
ahead. The most brilliant ideas appear when we meet each other face to face in a friendly
and open atmosphere.
The meeting has been organized by SLEuro, and the venue is Karolinska Institutet,
Aula Medica, which is close to Karolinska University Hospital. We invite you to attend
the free pre-conference meeting on Wednesday. It is open to everybody and will give
an overview of SLE research in Sweden. After the opening ceremony on Wednesday
afternoon we are all invited to Stockholm City Hall, where the Nobel Prize banquet is
held every December. On Friday we have a dinner at the Vasa Museum, where you will
be able to see the impressive and well-preserved Vasa ship, which sank on its maiden
voyage in the harbor of Stockholm in 1628. Make sure to stay until Saturday, when several
new therapies will be presented.
We know that the Covid-19 pandemic is not over, but we feel confident that we can
manage to implement the congress in a secure way. Consequently, we recommend all
participants take the Covid-19 vaccination in accordance with national recommendations
well before the meeting. Each of us needs to be considerate of our colleagues, friends,
and patients, and we urge you to be careful during the meeting.
We wish you all good health and welcome you to an exciting meeting in Stockholm.
Elisabet Svenungsson and Lars Rönnblom
Congress chairs
4
STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
EUROPEAN LUPUS SOCIETY – SLEuro
EXECUTIVE COMMITTEE
President
Elisabet Svenungsson, Sweden
President Elect
Laurent Arnaud, France
Past President
Frédéric Houssiau, Belgium
General Secretary
Luis Pedro Sousa Ines, Portugal
Treasurer
Andrea Doria, Italy
Members
Marta Alarcón-Riquelme, Spain
George Bertsias, Greece
Thomas Dörner, Germany
Maria Tektonidou, Greece
Angela Tincani, Italy
Carlos Vasconcelos, Portugal
Edward Vital, United Kingdom
SLEuro Secretariat
EUROPEAN LUPUS SOCIETY
Via G. Ripamonti, 129
20141 Milan (Italy)
Phone +39 02 566011
Fax +39 02 70048578
SLEuroSecretariat@aimgroup.eu
5
STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
COMMITTES
CONGRESS CHAIRPERSONS INTERNATIONAL SCIENTIFIC
E. Svenungsson, Stockholm – Sweden COMMITTEE
L. Rönnblom, Uppsala – Sweden N. Agmon-Levin, Tel-Hashomer (IL)
M. Alarcon Riquelme, Granada (ES)
PAST CHAIRS Z. Amoura, Paris (FR)
D. Boumpas, Athens (GR) H-J. Anders, München (DE)
S. Bombardieri, Pisa (IT) L. Andreoli, Brescia (IT)
R. Cervera, Barcelona (ES) M. Aringer, Dresden (DE)
N. Costedoat-Chalumeau, Paris (FR) L. Arnaud, Strasbourg (FR)
A. Doria, Padova (IT) G. Bertsias, Heraklion (GR)
F. Houssiau, Belgium (BE) D. Boumpas, Athens (GR)
D. Isenberg, London (UK) I. Bruce, Manchester (UK)
J. Kalden, Erlangen (DE) J. Buyon, New York (USA)
C. Kallenberg, Amsterdam (NL) R. Cervera, Barcelona (ES)
M. Khamashta, London (UK) C. Chizzolini, Genève (CH)
H.M. Moutsopoulos, Athens (GR) N. Costedoat-Chalumeau, Paris (FR)
M. Schneider, Düsseldorf (DE) P. Crow, New York (USA)
J. Smolen, Vienna (AT) D. D’Cruz, London (UK)
A. Tincani, Brescia (IT) A. Doria, Padua (IT)
C. Vasconcelos, Porto (PT) T. Dörner, Berlin (DE)
R. Fischer-Betz, Düsseldorf (DE)
LOCAL SCIENTIFIC COMMITTEE R. Furie, New York (USA)
E. Arkema, Stockholm (SE) F. Hiepe, Berlin (DE)
A. Bengtsson, Lund (SE) F. Houssiau, Leuven (BE)
I. Gunnarsson, Stockholm (SE) R. Ionescu, Bucharest (RO)
S. Jacobsen, Copenhagen (DK) D. Isenberg, London (UK)
D. Leonard, Uppsala (SE) M. Kahlenberg, Ann Arbor (USA)
S. Pettersson, Stockholm (SE) S. Manzi, Pittsburgh (USA)
C. Sjöwall, Linköping (SE) X. Mariette, Paris (FR)
C.C. Mok, Hong Kong (HK)
PATIENT SCIENTIFIC COMMITTEE E. Morand, Melbourne (AU)
J. Andersen (Knebel, DK) M. Mosca, Pisa (IT)
A. Cornet (Brussels, BE) T. Niewold, New York (USA)
Y. Enman (Stockholm, SE) D. Pisetsky, Durham (USA)
K. Sporre (Umeå, SE) B. Pons-Estel, Rosario (AR)
A. Rahman, London (UK)
G. Ruiz-Irastorza, Bizkaia (ES)
J. Salmon, New York (USA)
M. Schneider, Düsseldorf (DE)
L. Sousa Ines, Coimbra (PT)
Z. Szekanecz, Decrecen (HU)
M. Tektonidou, Athens (GR)
A. Tincani, Brescia (IT)
A.M. Troldborg, Aarhus (DK)
R. Van Vollenhoven, Amsterdam (NL)
C. Vasconcelos, Porto (PT)
E. Vital, Leeds (UK)
A. Voskuyl, Amsterdam (NL)
T. Vyse, London (UK)
6
WEDNESDAY 5TH OCTOBER 2022
hrs Auditorium (Aula Medica)
09:00 Registrations and Exhibition Opening, Fika
MEETING
13th EUROPEAN
LUPUS
09:30-11:00 Pre-Conference
11:00-11:30 Coffee break in Aula Medica
5-8 OCTOBER
STOCKHOLM
2022
11:30-13:00 Pre-Conference
13:00-14:00 Lunch
14:00-16:30 Pre-Conference
16:30-16:45
16:45-17:15 Welcome to Lupus 2022
7
17:15-17:45 70 years learning to use glucocorticoids in SLE
Interferons from discovery
17:45-18:15
to treatment in lupus
Transfer serivice from Aula Medica to the City Hall
18:30
(one-way only)
OPENING CEREMONY
19:00-21:00
at Stockholm CityHall
KEY Pre-Conference of the Congress sessions and Industry-sponsored *Fishbowls - *Health professionals
Lectures
LEGEND Swedish Society of Medicine oral communications symposia discussion rounds and patients sessions
*Not accreditedTHURSDAY 6TH OCTOBER 2022
Auditorium Sune Bergström´s Eva & Georg Klein Room
hrs
(Aula Medica) Auditorium (Bioclinicum) (Biomedicum 1)
MEETING
13th EUROPEAN
LUPUS
08:00-09:00
SLE epidemiology and
Disease mechanisms Disease activity and remission -
studies of subgroups
09:00-10:00 from the perspective of patient’s
5-8 OCTOBER
STOCKHOLM
2022
vs health professionals
10:00-10:20 Coffee break in Aula Medica
Activity and outcome
10:20-11:50 Genetics in SLE
with patients
INDUSTRY - SPONSORED
12:00-13:00
SYMPOSIUM
8
13:00-14:10 Lunch and E-Poster Discussion in Aula Medica
INDUSTRY - SPONSORED
14:10-15:40
SYMPOSIUM
Cardiovascular and
15:40-17:10 Immune system in SLE Old and new drugs in SLE
thrombotic disease
17:10-17:30 Coffee break in Aula Medica
Genesis enviroment,
17:30-19:00 Clinical challenges Cytokines and interferons
co-morbidities for patients/HPs
KEY Pre-Conference of the Congress sessions and Industry-sponsored *Fishbowls - *Health professionals
Lectures
LEGEND Swedish Society of Medicine oral communications symposia discussion rounds and patients sessions
*Not accreditedFRIDAY 7TH OCTOBER 2022
Sune Bergström´s Auditorium Eva & Georg Klein Room Nils Ringertz Room Peter Reichard Room Ragnar Granit Room
hrs Auditorium (Aula Medica)
(Bioclinicum) (Biomedicum 1) (Biomedicum 2) (Biomedicum 3) (Biomedicum 4)
SLEuro General
07:45-08:30
Assembly
MEETING
13th EUROPEAN
LUPUS
Antiphopholipid
08:30-09:30 Covid & infections
syndrome
09:30-09:50 Coffee break in Aula Medica
5-8 OCTOBER
STOCKHOLM
2022
NPSLE and
09:50-11:20 Nephritis associated symptoms
with patients
INDUSTRY - SPONSORED
11:30-13:00
SYMPOSIUM
13:00-14:10 Lunch and E-Poster Discussion in Aula Medica
9
INDUSTRY - SPONSORED
14:10-15:40
SYMPOSIUM
E-Poster station 1 Industry - Industry -
Patient should
(Aula Medica) How should anxiety Sponsored Sponsored
be involved
15:40-16:25 How is patient-centered and depression be Fishbowls Fishbowls
in all lupus
care best organized by targeted in SLE? Discussion Discussion
research!
a lupus team? rounds rounds
16:25-16:45 Coffee break in Aula Medica
Debate session: SLE - one
16:45-17:30
or several disease entities?
Steroids/HCQ and
17:30-18:10 Pregnancy & hormones
DMARDS
18:15-18:45 History of lupus
KEY Pre-Conference of the Congress sessions and Industry-sponsored *Fishbowls - *Health professionals
Lectures
LEGEND Swedish Society of Medicine oral communications symposia discussion rounds and patients sessions
*Not accreditedSATURDAY 8TH OCTOBER 2022
hrs Auditorium (Aula Medica)
MEETING
Targeting cytokines for lupus
13th EUROPEAN
LUPUS
08:30-09:00
drug develpoment
09:00-09:30 INDUSTRY - SPONSORED LECTURE
5-8 OCTOBER
STOCKHOLM
2022
Targeting B lineage cells in SLE: from today’s
09:30-10:00
experiences towards future possibilities
10:00-10:30 INDUSTRY - SPONSORED LECTURE
10:30-11:00 Coffee break in Aula Medica
10
Targeting the JAK-STAT signaling
11:00-11:30
in the development of SLE therapies
11:30-12:00 INDUSTRY - SPONSORED LECTURE
12:00-12:30 CLOSING CEREMONY
KEY Pre-Conference of the Congress sessions and Industry-sponsored *Fishbowls - *Health professionals
Lectures
LEGEND Swedish Society of Medicine oral communications symposia discussion rounds and patients sessions
*Not accreditedSTOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
WEDNESDAY 5TH OCTOBER 2022
PRE-CONFERENCE
Auditorium (Aula Medica)
09:30-09:40 Welcome
L. Rönnblom (Uppsala, SE)
09:40-10:00 Presentation of Ingegerd Johansson
C. Dahle (Linköping, SE)
10:00-10:30 SLE network and SLE in Sweden
L. Rönnblom (Uppsala, SE), E. Svenungsson (Stockholm, SE),
J. Sandling (Uppsala, SE)
10:30-11:00 Mitochondria in SLE
C. Lood (Washington, USA)
11:00-11:30 Coffee break
Systemic lupus erythematosus can be grouped into
11:30-11:45
four distinct sub-phenotypes
L.M. Diaz-Gallo (Stockholm, SE)
11:45-12:00 Prognostic biomarkers of organ damage in SLE
H. Enocsson (Linköping, SE)
12:00-12:15 Therapeutic targeting molecular pathways in SLE
K. Hjorton (Uppsala, SE)
12:15-12:30 Recent studies on the rituximab treated patients
F. Faustini (Stockholm, SE)
12:30-12:45 A decade of belimumab use in Sweden - What have we learnt?
I. Parodis (Stockholm, SE)
12:45-13:00 Infections in infants born to mothers with lupus
and the role of preterm birth
S. Gernaat (Stockholm, SE)
13:00-14:00 Lunch
11STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
WEDNESDAY 5TH OCTOBER 2022
Auditorium (Aula Medica)
14:00-14:15 SLE is one disease among the systemic autoimmune disease family
C. Lundtoft (Uppsala, SE)
14:15-14:30 The genetic background to disease manifestations in SLE
D. Leonard (Uppsala, SE)
14:30-14:45 Can we use polygenic risk scores to predict the SLE disease course?
S. Reid (Uppsala, SE)
14:45-15:00 Functional consequences for immune cells of SLE risk genes
N. Hagberg (Uppsala, SE)
15:00-15:15 Extracellular vesicles as autoantigens in systemic lupus erythematosus
F. Mobarrez (Uppsala, SE)
Reasons and consequences of a modest C-reactive protein response
15:15-15:30
in SLE
C. Sjöwall (Linköping, SE)
15:30-15:45 ROS-reducing genotypes in SLE and APS
A. Jern (Lund, SE)
15:45-16:00 Neuropsychiatric lupus - the Lund project
A. Jönsen (Lund, SE)
16:00-16:15 Immunological activation in blood and placenta for pregnancy
outcome in SLE
A.-C. Lundell (Gothenburg, SE)
16:15-16:30 Final words
E. Svenungsson (Stockholm, SE)
OPENING SESSION
Auditorium (Aula Medica)
16:45-17:15 WELCOME TO LUPUS 2022
L. Rönnblom (Uppsala, SE), E. Svenungsson (Stockholm, SE)
Auditorium (Aula Medica)
17:15-17:45 70 YEARS LEARNING TO USE GLUCOCORTICOIDS IN SLE
Chair: E. Svenungsson (Stockholm, SE)
Speaker: G. Ruiz-Irastorza (Bizkaia, ES)
Auditorium (Aula Medica)
17:45-18:15 INTERFERONS FROM DISCOVERY TO TREATMENT IN LUPUS
Chair: L. Rönnblom (Uppsala, SE)
Speaker: P. Crow (New York, USA)
19:00-21:00 OPENING CEREMONY AT STOCKHOLM CITY HALL
12STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Auditorium (Aula Medica)
08:00-10:00 DISEASE MECHANISMS
Chairs: L. Rönnblom (Uppsala, SE), A. Voskuyl (Amsterdam, NL)
08:00-08:20 Initial events in the SLE disease process
D. Boumpas (Athens, GR)
08:20-08:40 The generation and impact of autoantibodies
D. Pisetsky (Durham, USA)
08:40-09:00 NETs - are they good or harmful?
M. Kaplan (Bethesda, USA)
09:00-09:20 The platelet in SLE - small but important
A. Bengtsson (Lund, SE)
09:20-09:30 EXTRAMEDULLARY HEMATOPOIESIS AND IMMUNE TRAINING
CONTRIBUTE TO TISSUE INFLAMMATION IN SLE BY PROVIDING
INFLAMMATORY LICENSE TO BONE MARROW-DERIVED
HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS)
E. Zervopoulou, S. Doumas, A. Banos, H. Gakiopoulou, I. Mitroulis,
D.T. Boumpas, M. Grigoriou
(Athens, GR)
09:30-09:40 BANK1 SIGNALING SHAPES THE GUT MICROBIOTA COMPOSITION
BY CONTROLLING THE GUT MUCOSAL B CELL RESPONSE IN LUPUS
G. Galicia, M. Botia Sanchez, M.E. Alarcon-Riquelme
(Granada, ES)
09:40-09:50 RNA-SEQ IN PERIPHERAL BLOOD IMMUNE CELLS IDENTIFIES
MODULAR NETWORKS PREDICTIVE AND PROTECTIVE FOR
PROGRESSION FROM ANA POSITIVITY TO CLASSIFIABLE SYSTEMIC
AUTOIMMUNE DISEASE
L. Carter, A. Psarras, Z. Wigston, M.Y. Md Yusof, E. Vital
(Leeds, UK)
09:50-10:00 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS
WITH SYSTEMIC LUPUS ERYTHEMATOSUS
1
E.J. Arends, 1M.Zlei, 2C.M. Tipton, 1Z. Osmani, 1F.J. De Bie, 1S.W. Kamerling,
1
T.J. Rabelink, 2I. Sanz, 1J.J. Van Dongen, 1C. Van Kooten, 1Y.O. Teng2
(1Leiden, NL, 2Atlanta, USA)
13STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Sune Bergström´s Auditorium (Bioclinicum)
08:00-10:00 SLE EPIDEMIOLOGY AND STUDIES OF SUBGROUPS
Chairs: B. Pons-Estel (Rosario, AR), M. Tektonidou (Athens, GR)
08:00-08:20 Clinical differences between juvenile and adult onset lupus
S. Kamphuis (Rotterdam, NL)
08:20-08:40 Men with SLE
L. Arnaud (Strasbourg, FR)
08:40-09:00 Epidemiology in Scandinavia
E. Arkema (Stockholm, SE)
09:00-09:30 Round table discussion
E. Arkema (Stockholm, SE), L. Arnaud (Strasbourg, FR),
S. Kamphuis (Rotterdam, NL)
09:30-09:40 INCIDENCE AND PREVALENCE OF SYSTEMIC LUPUS
ERYTHEMATOSUS IN A LARGE POPULATION-BASED STUDY IN
NORTH-EASTERN ITALY, BETWEEN 2012 AND 2020
M. Zen, L. Salmaso, C. Barbiellini Amidei, E. Fuzzi, U. Fedeli, S. Bellio,
L. Iaccarino, M. Saia, A. Doria
(Padua, IT)
09:40-09:50 GENDER DIFFERENCES IN TRENDS OF INCIDENCE IN SYSTEMIC
LUPUS ERYTHEMATOSUS IN NORWAY; ESTIMATES FROM A
POPULATION-BASED COHORT
1
H. Haukeland, 1S. Reppe Moe, 1C. Brunborg, 1T. Garen, 2A. Botea,
3
N. Damjanic, 4G. Wivestad, 5H. Øvreås, 6T. Bøe, 7A. Orre, 1 Ø. Molberg,
1
K. Lerang.
(1Oslo, NO, 2Skien, NO, 3Moss, NO, 4Kristiansand, NO, 5Lillehammer, NO,
6
Tønsberg, NO, 7Drammen, NO)
09:50-10:00 CHANGES IN THE CAUSES AND PREDICTORS OF LUPUS MORTALITY
IN SPAIN THROUGH THE LAST DECADES: DATA FROM THE
RELESSER REGISTRY
C. Moriano1, J. Calvo-Alén2, I. Rúa-Figueroa3, E. Diez Alvarez1,
C. Bermúdez1, F.J. López-Longo4, M. Galindo-Izquierdo4, A. Olivé5,
E. Tomero Muriel4, A. Fernández-Nebro6, M. Freire González7,
O. Fernández-Berrizbeitia10, A. Pérez Gómez4, E. Uriarte Isacelaya9,
C. Marras10, C. Montilla-Morales11, G. Santos Soler12, R. Blanco13,
M. Rodríguez-Gómez14, P. Vela-Casasempere15, A. Boteanu4,
J. Narváez16, V. Martínez-Taboada16, B. Hernández-Cruz17, J.L. Andreu4,
J.A. Hernández-Beriain3, L. Expósito18, R. Menor-Almagro19,
M. Ibañez-Barceló20, I. Castellví21, C. Galisteo22, E. Raya23,
V. Quevedo Vila24, T. Vázquez Rodríguez25, J. Ibañez26, J.M. Pego-Reigosa26
(1León, ES, 2Vitoria, ES, 3Las Palmas de Gran Canaria, ES, 4Madrid,
ES,5Badalona, ES, 6Málaga, ES, 7A Coruña, ES, 8Bilbao, ES, 9San
Sebastián, ES, 10Murcia, ES, 11Salamanca, ES, 12Villajoyosa, ES,
13
Santander, ES, 14Ourense, ES, 15Alicante, ES, 16Hospitalet, ES, 17Sevilla,
ES, 18Tenerife, ES, 19Jerez de la Frontera, ES, 20Palma de Mallorca, ES,
21
Barcelona, ES, 22Sabadell, ES, 23Granada, ES, 24Monfortede Lemos, ES,
25
Lugo, ES, 26Vigo, ES)
14STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Eva & George Klein Room (Biomedicum 1) NO CME ACTIVITY
09:00-10:00 DISEASE ACTIVITY AND REMISSION - FROM THE PERSPECTIVE OF
PATIENT´S VS HEALTH PROFESSIONALS
Chairs: J. Andersen (Knebel, DK), M. Karlsson (Stockholm, SE)
09.00-09:20 Measuring disease activity & remission
E. Morand (Melbourne, AU)
09:20-09:30 The clinical use of SLAQ/Q-SLAQ?
S. Pettersson (Stockholm, SE)
09:30-10:00 What are my key concerns when I am having a lupus flare?
A. Cornet (Brussels, BE)
10:00-10:20 Coffee break in Aula Medica
Auditorium (Aula Medica)
10:20-11:50 ACTIVITY AND OUTCOME WITH PATIENTS
Chairs: D. D’Cruz (London, UK), E. Morand (Melbourne, AU)
10:20-10:40 How can we improve measurements of disease activity?
L.P. Sousa Ines (Coimbra, PT)
10:40-11:00 Updating the SLICC Damage index, report from ongoing work
I. Bruce (Manchester, UK)
What are we aiming for? Is remission/low disease activity, realistic
11:00-11:20
in all patients?
A. Doria (Padua, IT)
What are we aiming for?
11:20-11:40
J. Andersen (Knebel, DK)
11:40-11:50 TREAT TO TARGET IN SYSTEMIC LUPUS ERYTHEMATOSUS FROM
THE PATIENTS’ PERSPECTIVE–RESULTS FROM AN INTERNATIONAL
PATIENT SURVEY
1
J. Mucke, 2D. Pencheva, 3A. Parra Sanchez, 3K. Cramer, 1M. Schneider,
3
I. Bultink
(1Düsseldorf, DE, 2Sofia, BG, 3Amsterdam, NL)
15STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Sune Bergström´s Auditorium (Bioclinicum)
10:20-11:50 GENETICS IN SLE
Chairs: D. Leonard (Uppsala, SE), T. Niewold (New York, USA)
10:20-10:40 The spectrum of risk genes in SLE
T. Vyse (London, UK)
10:40-11:00 How genetics and genomics stratify patients with SLE
M. Alarcon-Riquelme (Granada, ES)
11:00-11:20 The epigenetic contribution to SLE
C. Lanata (Washington, USA)
11:20-11:30 GENETIC EVALUATION OF MOLECULAR TRAITS IN SYSTEMIC
LUPUS ERYTHEMATOSUS
1
O. Castellini-Pérez, 2A. Iakovliev, 1M. Martínez-Bueno, 1G. Barturen,
1
M.E. Alarcón-Riquelme, 1E. Carnero-Montoro, 2A. Spiliopoulou.
(1Granada, ES, 2Edinburgh, UK)
11:30-11:40 INTERACTION BETWEEN HLA-DRB1*03:01 AND STAT4 IS ASSOCIATED
WITH INCREASED RISK OF NEPHRITIS IN SYSTEMIC LUPUS
ERYTHEMATOSUS
1
E. Lundqvist, 1S. Reid, 1A. Sayadi, 1M. Eloranta, 1E. Skoglund, 1K. Bolin,
2
M. Frodlund, 3K. Lerang, 4A. Jönsen, 5S. Rantapää-Dahlqvist,
4
A. Bengtsson, 6A. Rudin, 3 Ø. Molberg, 2C. Sjöwall, 1J.K. Sandling,
1
L. Rönnblom, 1D. Leonard.
(1Uppsala, SE, 2Linköping, SE, 3Oslo, NO, 4Lund, SE, 5Umeå, SE,
6
Gothenburg, SE)
11:40-11:50 GENETICAL AND PHENOTYPICAL FINDINGS OF CHILDHOOD-ONSET
SYSTEMIC LUPUSERYTHEMATOSUS
P. Morán Álvarez, C. Passarelli, V. Messia, M. Pardeo, E. Marasco,
A. Insalaco, F. De Benedetti, C. Bracaglia
(Rome, IT)
Auditorium (Aula Medica)
12:00-13:00 INDUSTRY-SPONSORED SYMPOSIUM - see page n. 65
13:00-14:10 Lunch and E-poster discussion in Aula Medica
Auditorium (Aula Medica)
14:10-15:40 INDUSTRY-SPONSORED SYMPOSIUM - see page n. 65
16STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Auditorium (Aula Medica)
15:40-17:10 CARDIOVASCULAR AND THROMBOTIC DISEASE
Chairs: L. Andreoli (Brescia, Italy), E. Svenugsson (Stockholm, SE)
15:40-16:00 Myocardial infarctions, stratification and treatment
P. Tornvall (Stockholm, SE)
16:00-16:20 Atherosclerosis in SLE and APS
M. Tektonidou (Athens, GR)
16:20-16:40 Non-atherosclerotic cardiovascular disease in SLE and APS
S. Jacobsen (Copenhagen, DK)
16:40-16:50 ENDOTHELIAL FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS
PATIENTS: IMPACT OF CAFFEINE CONSUMPTION ON ENDOTHELIAL
PROGENITOR CELLS SURVIVAL
V. Orefice, F. Ceccarelli, C. Barbati, E. Putro, C. Pirone, C. Alessandri, F. Conti
(Rome, IT)
16:50-17:00 PATTERNS OF RECURRENT THROMBOSIS IN PRIMARY
ANTIPHOSPHOLIPID SYNDROME–MULTICENTRE, REAL LIFE LONG
TERM FOLLOW-UP
1
S. Niznik, 2M. Rapoport, 3O. Avnery, 3M. Ellis, 1A. Lubetsky, 1S. Haj Yahia,
1
N. Agmon-Levin.
(1Ramat Gan, IS, 2Zerifin, IS, 3KfarSaba, IS)
17:00-17:10 PATIENT-SPECIFIC AND DISEASE-RELATED DETERMINANTS
FOR CARDIOVASCULARDISEASE (CVD) RISK STRATIFICATION
IN THE APPLE (ATHEROSCLEROSIS PREVENTIONIN PAEDIATRIC
LUPUS ERYTHEMATOSUS) CLINICAL TRIAL COHORT
J. Peng1, G. Robinson1, E. Jury1, S. Ardoin2, L. Schanberg3, C. Ciurtin1
(1London, UK, 2Columbus, USA, 3Durham, USA)
17STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Sune Bergström´s Auditorium (Bioclinicum)
15:40-17:10 IMMUNE SYSTEM IN SLE
Chairs: P. Crow (New York, USA), C. Sjöwall (Linköping, SE)
15:40-16:00 Inside out cell death as driver for anti-nuclear autoimmunity
M. Herrmann (Erlangen, DE)
16:00-16:20 What can we learn from single-cell RNA sequencing?
T. Niewold (New York, USA)
16:20-16:40 How important is the complement system?
A. Blom (Lund, SE)
16:40-16:50 STRATIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
PATIENTS BASED ON THE MOLECULAR PATTERNS OF MOUSE MODELS
M. Rivas-Torrubia1, M. Morell1, Z. Makowska2, J. Kageyama2,
A. Buttgereit2, PRECISESADS cytometry consortium1, R. Lesche2,
F. McDonald2, M. Alarcón-Riquelme1, G. Barturen-Briñas1,
(1Granada, ES, 2Berlin, DE)
16:50-17:00 EFFICACY AND SAFETY OF DEUCRAVACITINIB, A SELECTIVE TYK2
INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS
ERYTHEMATOSUS: RESULTS FROM A PHASE2, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
R. van Vollenhoven1, M. Pike2, J.T. Merrill3, E. Morand4, V.P. Werth5,
C. Hobar6, N. Delev6, V. Shah6, B. Sharkey6, T. Wegman6, I. Catlett6,
S. Banerjee6, S. Singhal6
(1Amsterdam, NL, 2Raleigh, USA, 3Oklahoma City, USA, 4Victoria, AU,
5
Philadelphia, USA, 6Princeton, USA)
17:00-17:10 LOW-DOSE INTERLEUKIN-2 THERAPY IN ACTIVE SYSTEMIC LUPUS
ERYTHEMATOSUS (LUPIL-2): A MULTI-CENTER, DOUBLE-BLIND,
RANDOMIZED AND PLACEBO-CONTROLLED PHASE 2 TRIAL
2
J. Humrich, 1P. Cacoub, 1M. Rosenzwajg, 1F. Pitoiset, 1H. Pham,
1
J. Guidoux, 1D. Leroux, 1T. Vazquez, 2G. Riemekasten, 3J. Smolen,
4
G. Tsokos, 1D. Klatzmann.
(1Lübeck, DE, 2Paris, FR, 3Wien, AT, 4Boston, USA)
Eva & George Klein Room (Biomedicum 1) NO CME ACTIVITY
15:40-17:10 OLD AND NEW DRUGS IN SLE
Chairs: A. Somers (Manchester, UK), C. Vasconcelos (Porto, PT)
15:40-16:00 Corticosterids & antimalaria
D. D´Cruz (London, UK)
16:00-16:20 DMARD-bDMARD
A. Rahman (London, UK)
16:20-16:40 New treatments in the pipeline
F. Hiepe (Berlin, DE)
16:40-17:10 Medical adherence
K. Myllys (Helsinki, FI)
17:10-17:30 Coffee break in Aula Medica
18STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Auditorium (Aula Medica)
17:30-19:00 CLINICAL CHALLENGES
Chairs: N. Agmon-Levin (Tel-Hashomer, IL), G. Nordmark (Uppsala, SE)
17:30-17:50 Sjögren’s syndrome in lupus, does it change anything?
X. Mariette (Paris, FR)
17:50-18:10 Refractory skin manifestations
M. Kahlenberg (Ann Arbor, USA)
18:10-18:30 Approaching a patient with possible NPSLE
B. Diamond (New York, USA)
18:30-18:40 DISEASE ACTIVITY AND CLINICAL REMISSION IN SYSTEMIC LUPUS
ERYTHEMATOSUS: COMPARISON BETWEEN PATIENT AND
PHYSICIAN PERSPECTIVES BY MEANS OF PATIENT REPORTED
OUTCOMES (PROS)
M. Fredi, C. Orlandi, M. Salvi, C. Bazzani, C. Nalli, L. Andreoli,
F. Franceschini.
(Brescia, IT)
18:40-18:50 MEDICATION ADHERENCE IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS: RESULTS FROM A SWEDISH SURVEY
S. Emamikia1, A. Gomez Gonzalez1, T. Ådahl2, G. von Perner1, Y. Enman1,
K. Chatzidionysiou1, E. Arkema1, I. Parodis1,2
(1Stockholm, SE, 2Örebro, SE)
18:50-19:00 DISCUSSION
19STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
THURSDAY 6TH OCTOBER 2022
Sune Bergström´s Auditorium (Bioclinicum)
17:30-19:00 CYTOKINES AND INTERFERONS
Chairs: C. Chizzolini (Geneva, CH), V. Oke (Stockholm, SE)
17:30-17:50 Biomarkers for SLE - which are they?
J.A. James (Oklahoma City, USA)
17:50-18:10 Interferon producing cells in SLE
M.-L. Eloranta (Uppsala, SE)
18:10-18:30 Tissues specific IFN gene signatures
E. Vital (Leeds, UK)
18:30-18:40 IL-16-A URINARY BIOMARKER FOR PROLIFERATIVE LUPUS
NEPHRITIS
1
A. Häyry, 1F. Faustini, 1A. Zickert, 2A. Larsson, 1B. Sundelin,
1
E. Svenungsson, 1V. Oke, 1I. Gunnarsson
(1Stockholm, SE, 2Uppsala, SE)
18:40-18:50 TYPE I INTERFERONS AND THEIR AUTOANTIBODIES IN THE
CONTEXT OF SYSTEMIC LUPUS ERYTHEMATOSUS
1
L. Haljasmägi, 2H. Bradford, 3M. Menon, 1P. Peterson, 1M. Vanker,
2
C. Wincup, 4V. Bondet, 4D. Duffy, 2D. Isenberg, 1K. Kisand, 2C. Mauri
(1Tartu, EE, 2London, UK, 3Manchester, UK, 4Paris, FR)
18:50-19:00 TYPE I INTERFERONS INDUCE TIE2-MEDIATED ENDOTHELIAL CELL
DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS
C. Rafael Vidal, S. Martínez Ramos, B. Malvar Fernández,
C. Mouriño Rodríguez, I. Altabás González, J.M. Pego Reigosa,
S. García Pérez
(Vigo, ES)
Eva & George Klein Room (Biomedicum 1) NO CME ACTIVITY
17:30-19:00 GENES, ENVIRONMENT, CO-MORBIDITIES FOR PATIENTS/HPS
Chairs: A. Bengtsson (Lund, SE), Y. Enman (Stockholm, SE)
17:30-17:50 What can genetics tell us?
J. Sandling (Uppsala, SE)
17:50-18:10 Genes and environment in SLE
S. Reid (Uppsala, SE)
18:10-18:40 Comorbidities
A. Tincani (Brescia, IT)
18:40-19:00 Patient research partner
M. Karlsson (Stockholm, SE)
20STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
FRIDAY 7TH OCTOBER 2022
Eva & George Klein Room (Biomedicum 1)
07:45-08:30 SLEuro general assembly
Auditorium (Aula Medica)
08:30-09:30 COVID & INFECTIONS
Chairs: M. Mosca (Pisa, IT), A. Troldborg (Aarhus, DK)
08:30-08:50 The immune response to SARS-CoV-2
F. Kurth (Berlin, DE)
08:50-09:10 Covid vaccination in SLE
Z. Amoura (Paris, FR)
09:10-09:20 EFFICACY AND SAFETY OF THE ANTI-SARS-COV-2 BNT162B2
VACCINE AMONG SLE PATIENTS: THE COVALUS PROJECT
A. Mageau, V. Ferré, P. Nicaise Roland, T. Papo, T. Goulenok, J. Tchen,
N.Charles, K. Sacre
(Paris, FR)
09:20-09:30 RISK OF COVID-19 INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS
FLARE: ANALYSIS OF THE AP-HP CLINICAL DATA WAREHOUSE
A. Mageau, T. Papo, J. Timsit, K. Sacre
(Paris, FR)
Sune Bergström´s Auditorium (Bioclinicum)
08:30-09:30 ANTIPHOPHOLIPID SYNDROME
Chairs: A. Antovic (Stockholm, SE), A. Tincani (Brescia, IT)
08:30-08:50 CAPS update on treatment and outcomes
R. Cervera (Barcelona, ES)
08:50-09:10 Which tests to measure antiphospholipid antibodies?
V. Pengo (Padua, IT)
09:10-09:20 DEVELOPING SYSTEMIC AUTOIMMUNE DISEASES IN HEALTHY
SUBJECTS PERSISTENTLY POSITIVE FOR ANTIPHOSPHOLIPID
ANTIBODIES: LONG-TERM FOLLOW-UP STUDY
F. Ceccarelli, F. Natalucci, G. Olivieri, C. Pirone, L. Picciariello, V. Orefice,
F.R. Spinelli, C. Alessandri, A. Chistolini, F. Conti
(Rome, IT)
09:20-09:30 ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN ANTIBODIES AND
THROMBOSIS ASSOCIATE POSITIVELY WITH HLA-DRB1*13 AND
NEGATIVELY WITH HLA-DRB1*03 IN SLE
1
S. Elbagir, 2L. Diaz-Gallo, 2G. Grosso, 2A. Zickert, 2I. Gunnarsson,
3
M. Mahler, 2E. Svenungsson, 1J. Rönnelid.
(1Uppsala, SE, 2Stockholm, SE, 3San Diego, USA)
09:30-09:50 Coffee break in Aula Medica
21STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
FRIDAY 7TH OCTOBER 2022
Auditorium (Aula Medica)
09:50-11:20 NEPHRITIS
Chairs: F. Hiepe (Berlin, DE), A. Zickert (Stockholm, SE)
09:50-10:10 Lupus nephritis in context of renal disease
H.-J. Anders (Munich, DE)
10:10-10:30 Renal biopsies, what do they tell us?
I. Gunnarsson (Stockholm, SE)
10:30-10:50 Update on lupus nephritis treatment: new options, at last!
F. Houssiau (Brussels, BE)
10:50-11:00 B CELL KINETICS UPON THERAPY COMMENCEMENT FOR ACTIVE
EXTRA-RENAL SYSTEMIC LUPUS ERYTHEMATOSUS IN RELATION
TO DEVELOPMENT OF RENAL FLARES
I. Parodis1, A. Gomez1, J. Lindblom1, J.W. Chow1, C. Sjöwall2, S. Sciascia3,
M. Gatto4
(1Stockholm, SE, 2Linköping, SE, 3Turin, IT, 4Padua, IT)
11:00-11:10 LONG-TERM EFFICACY AND SAFETY OF VOCLOSPORIN WITH MMF
AND LOW-DOSE STEROIDS: DATA FROM THE AURORA 2
CONTINUATION STUDY
K. Gibson1, Y.K.O. Teng2, L. Hodge3, C. Collins3
(1Chapel Hill, USA, 2Leiden, NL, 3Victoria, CA)
11:10-11:20 EVALUATION OF PREDICTIVE FACTORS OF WORSE PROGNOSIS IN
LUPUS NEPHRITIS: FOCUS ON NEW PATHOGENETIC PATHWAYS
V. Varriano, A. Paglionico, L. Petricca, C. Di Mario, M. Gigante,
B. Tolusso, E. Gremese
(Rome, IT)
22STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
FRIDAY 7TH OCTOBER 2022
Sune Bergström´s Auditorium (Bioclinicum)
09:50-11:20 NPSLE AND ASSOCIATED SYMPTOMS WITH PATIENTS
Chairs: L. Arnaud (Strasbourg, FR), A. Jönsen (Lund, SE)
09:50-10:10 The clinical spectrum of NPSLE
M. Steeup-Beekman (Leiden, NL)
10:10-10:30 To visualize brain involvement in SLE
P.C. Sundgren (Lund, SE)
10:30-10:50 What are the patients’ main concerns?
S. Pettersson (Stockholm, SE)
10:50-11:00 THE EFFECT OF ANTI-RIBOSOMAL-P AND ANTI-DWEYS
ANTIBODIES ON DEPRESSION AND BEHAVIORAL COGNITIVE
PROCESSES IN SYSTEMIC LUPUS ERYTHEMATOSUS: AN INTEGRATED
CLINICAL AND FUNCTIONAL MRI STUDY
1
E. Chessa, 1M. Porcu, 1E. Pintus, 1A. Perra, 2A. Floris, 1M.M. Angioni,
1
M. Congia, 1M.G. Carta, 1L. Saba, 2A. Mathieu, 2A. Cauli, 1,2M. Piga
(1Cagliari, IT, 2Monserrato, IT)
11:00-11:10 FAVORABLE OUTCOME OF PATIENTS WITH INFLAMMATORY
NEUROPSYCHIATRIC LUPUS TREATED WITH IMMUNOSUPPRESSION
R. Monahan, L. Beaart-van de Voorde, R. Fronczek, J. de Bresser,
J. Eikenboom, M. Kloppenburg, H. Middelkoop, G. Terwindt,
N. van der Wee, T. Huizinga, M. Steup-Beekman
(Leiden, NL)
11:10-11:20 COGNITIVE DYSFUNCTION IS COMMON BUT ASSOCIATES WEAKLY
WITH QUALITY OF LIFE IN PATIENTS WITH LUPUS AND
NEUROPSYCHIATRIC SYMPTOMS
R. Monahan, H. Middelkoop, L. Beaart-van de Voorde, R. Fronczek,
M. Kloppenburg, T. Huizinga, M. Steup-Beekman
(Leiden, NL)
Auditorium (Aula Medica)
11:30-13:00 INDUSTRY-SPONSORED SYMPOSIUM - see page n. 67
13:00-14:10 Lunch and E-poster discussion in Aula Medica
Auditorium (Aula Medica)
14:10-15:40 INDUSTRY-SPONSORED SYMPOSIUM - see page n. 68
23STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
FRIDAY 7TH OCTOBER 2022
E-Poster station 1 in Aula Medica NO CME ACTIVITY
15:40-16:25 FISHBOWLS - DISCUSSION ROUNDS
HOW IS PATIENT-CENTERED CARE BEST ORGANIZED BY A LUPUS
TEAM?
Chair: A. Cornet (Brussels, BE)
Discussants: N. Costedoat-Chalumeau (Paris, FR), R. Ionescu (RO),
M. Mosca (Pisa, IT), S. Pettersson (Stockholm, SE)
Eva & George Klein Room (Biomedicum 1) NO CME ACTIVITY
15:40-16:25 FISHBOWLS - DISCUSSION ROUNDS
HOW SHOULD ANXIETY AND DEPRESSION BE TARGETED IN SLE?
Chair: M. Aringer (Dresden, DE),
Discussants: J. Andersen (Knebel, DK), D. Boumpas (Athens, GR),
E. Morand (Melbourne, AU), A. Rahman (London, UK),
K. Sporre (Umeå, SE)
Nils Ringertz Room (Biomedicum 2) NO CME ACTIVITY
15:40-16:25 FISHBOWLS - DISCUSSION ROUNDS
PATIENT SHOULD BE INVOLVED IN ALL LUPUS RESEARCH!
Chair: J. Mucke (Düsseldorf, DE)
Discussants: M. Alarcon Riquelme (Granada, ES), T. Dörner (Berlin, DE),
Y. Enman (Stockholm, SE), S. Jacobsen (Copenhagen, DK),
C. Sjöwall (Linköping, SE)
Peter Reichart Room (Biomedicum 3)
15:40-16:25 INDUSTRY-SPONSORED FISHBOWL - DISCUSSION ROUNDS
see page n. 68
Ragnar Granit Room (Biomedicum 4)
15:40-16:25 INDUSTRY-SPONSORED FISHBOWL - DISCUSSION ROUNDS
see page n. 68
16:25-16:45 Coffee break in Aula Medica
Auditorium (Aula Medica)
16:45-17:30 DEBATE SESSION: SLE - ONE OR SEVERAL DISEASE ENTITIES?
Chair: D. Isenberg (London, UK)
Speakers: M. Aringer (Dresden, DE) vs R. Van Vollenhoven (Amsterdam, NL)
Auditorium (Aula Medica)
17:30-18:10 PREGNANCY & HORMONES
Chairs: R. Fischer-Betz (Düsseldorf, DE), A. Rudin (Gothenburg, SE)
17:30-17:50 Can we predict and prevent pregnancy complications in patients
with lupus and APS?
J. Salmon (New York, USA)
17:50-18:10 Neonatal lupus
J. Buyon (New York, USA)
24STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
FRIDAY 7TH OCTOBER 2022
Sune Bergström´s Auditorium (Bioclinicum)
17:30-18:10 STEROIDS/HCQ AND DMARDS
Chairs: R. Ionescu (Bucharest, RO), G. Ruiz-Irastorza (Bizkaia, ES)
17:30-17:50 HCQ, for how long, are there limitations?
N. Costedoat-Chalumeau (Paris, FR)
17:50-18:00 HYDROXYCHLOROQUINE DAILY DOSE, HYDROXYCHLOROQUINE
BLOOD LEVELS AND THE RISK OF FLARES IN PATIENTS WITH
SYSTEMIC LUPUS ERYTHEMATOSUS
S. Fasano, V. Messiniti, E. Gaggiano, A. Milone, M. Patrone, F. Riccio,
F. Ciccia
(Naples, IT)
18:00-18:10 SEVERE NON-ADHERENCE TO HYDROXYCHLOROQUINE IS
ASSOCIATED WITH FLARES, EARLY DAMAGE, AND MORTALITY IN
SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM 660 PATIENTS
FROM THE SLICC INCEPTION COHORT
1
Y. Nguyen, 1B. Blanchet, 2M.B. Urowitz, 3J.G. Hanly, 4C. Gordon, 5S. Bae,
6
J. Romero-Dia, 7J. Sanchez-Guerrero, 2A.E. Clarke, 8S. Bernatsky,
9
D.J. Wallace, 10D.A. Isenberg, 10A. Rahman, 11J.T. Merrill, 12P.R. Fortin,
2
D.D. Gladman, 13I.N. Bruce, 14M. Petri, 15E.M. Ginzler, 16M.A. Dooley,
17
R. Ramsey-Goldman, 18S. Manzi, 19A. Jönsen, 4G.S. Alarcón,
21
R.F. Van Vollenhoven, 22C. Aranow, 1V. Le Gurn, 15M. Mackay,
24
G. Ruiz-Irastorza, 25S. Lin, 26M. Inanc, 29K.C. Kalunian, 30S. Jacobsen,
31
C.A. Peschken, 32D.L. Kamen, 33A. Askanase, 34J. Buyon,
1
N. Costedoat-Chalumeau
(1Paris, FR, 2Toronto, CA, 3Halifax, CA, 4Birmingham, UK, 5Seoul, KR,
6
Mexico City, MX, 7Calgary, CA, 8Montreal, CA, 9Los Angeles, USA,
10
London, UK, 11Oklahoma City, USA, 12Québec, CA, 13Manchester, UK,
14
Baltimore, USA, 15New York, USA, 16Chapel Hill, USA, 17Chicago,
USA, 18Pittsburgh, USA, 19Lund, SE, 20Amsterdam, NL, 21Manhasset,
USA, 22Bizkaia, ES, 23Atlanta, USA, 24Istanbul, TR, 25La Jolla, USA,
26
Copenhagen, DK, 27Winnipeg, CA, 28Charleston, USA)
Auditorium (Aula Medica)
18:15-18:45 HISTORY OF LUPUS
Chair: M. Schneider (Düsseldorf, DE)
Speaker: D. Isenberg (London, UK)
25STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
SATURDAY 8TH OCTOBER 2022
Auditorium (Aula Medica)
08:30-09:00 TARGETING CYTOKINES FOR LUPUS DRUG DEVELOPMENT
Chair: A. Rahman (London, UK)
Speaker: R. Furie (New York, USA)
Auditorium (Aula Medica)
09:00-09:30 INDUSTRY-SPONSORED LECTURE - see page n. 69
Auditorium (Aula Medica)
09:30-10:00 TARGETING B LINEAGE CELLS IN SLE: FROM TODAY’S EXPERIENCES
TOWARDS FUTURE POSSIBILITIES
Chair: M. Tektonidou (Athens, GR)
Speaker: T. Dörner (Berlin, DE)
Auditorium (Aula Medica)
10:00-10:30 INDUSTRY-SPONSORED LECTURE - see page n. 69
10:30-11:00 Coffee break in Aula Medica
Auditorium (Aula Medica)
11:00-11:30 TARGETING THE JAK-STAT SIGNALING IN THE DEVELOPMENT
OF SLE THERAPIES
Chair: E. Morand (Melbourne, AU)
Speaker: C.C. Mok (Hong Kong, HK)
Auditorium (Aula Medica)
11:30-12:00 INDUSTRY-SPONSORED LECTURE - see page n. 69
Auditorium (Aula Medica)
12:00-12:30 CLOSING CEREMONY
L. Rönnblom (Uppsala, SE), E. Svenungsson (Stockholm, SE)
26STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
E- POSTER SESSION 1:
ANIMAL MODELS, OMICS IN LUPUS, MAJOR ORGAN INVOLVEMENT
INCLUCING NPSLE, ORGAN DAMAGE AND SURVIVAL
Chair: M. Hermann (Erlangen, DE)
PO1:01 • AFIMETORAN, A POTENT AND SELECTIVE INHIBITOR OF HUMAN TOLL-LIKE
RECEPTOR 7 (TLR7) AND TLR8, PROVIDES ROBUST EFFICACY IN A MURINE LUPUS
MODEL OF ADVANCED DISEASE
S. Dudhgaonkar1, A. Rudra1, S. Ranade1, S. Subramani1, J. Nagar1, P. Karunanithi1,
P. Bhutani1, V. Kurawattimath1, R. Zhang2, H. Qiu2, A. Dyckman2, G. Schieven2
(1Bangalore, India, 2New Jersey, USA)
PO1:02 • BANK1 HAS A DETERMINANT ROLE IN THE PRESENCE OF AGE-ASSOCIATED
B CELLS IN AUTOIMMUNITY
G. Gómez Hernández, M. Morell Hita, M. Alarcón-Riquelme
(Granada, ES)
PO1:03 • IL-18 DEFICIENCY DOES NOT AFFECT DEVELOPMENT OF RENAL TERTIARY
LYMPHOID STRUCTURES IN IMIQUIMOD INDUCED SLE
K. Fenton, T.E. Olsen, A.M.K. Hovd, P. Kanapathippillai, A. Ursvik, C. Lemoin, S. Figenschau,
H.L. Pedersen
(Tromsoe, NO)
PO1:04 • THE EIF4 TRANSLATIONAL INHIBITOR PATEAMINE A IMPROVES
IMMUNOLOGICAL AND NEUROLOGICAL FUNCTIONS IN BXSB.YAA LUPUS MICE
M. Morell Hita1, H. Bagavant2, G. Gómez-Hernández1, N. Varela1, G. Barturen1,
M. Alarcón-Riquelme1
(1Granada, ES, 2Oklahoma, USA)
PO1:05 • SCORING PERSONALIZED MOLECULAR PORTRAITS IDENTIFY SYSTEMIC
LUPUS ERYTHEMATOSUS SUBTYPESAND PREDICT TRANSCRIPTIONAL DRUG
RESPONSES, SYMPTOMATOLOGY AND DISEASE PROGRESSION
D. Toro Dominguez1, M. Martínez Bueno1, R. López Domínguez1, J. Martorell Marugan1,
E. Carnero Montoro1, G. Barturen1, D. Goldman2, M. Petri2, P. Carmona Saez1,
M. Alarcón-Riquelme1,3
(1Granada, ES, 2Baltimore, USA, 3Solne, SE)
PO1:06 • INVESTIGATING MONOCYTE TRANSCRIPTOMICS AND TARGETED
PROTEOMICS SIGNATURES IN SLE WITH ATHEROSCLEROSIS UNCOVERS
HETEROGENEITY IN INFLAMMATORY PROFILES
L. Woodridge1, P. Ashford1, G. Robinson1, K. Waddington1, A. Rahman1, C. Orengo1, L. Jury1,
I. Pineda-Torra1, E. Chocano Navarro2
(1London, UK, 2Barcelona, ES)
PO1:07 • URINARY METABOLOMIC PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS
AND LUPUS NEPHRITIS BASED ON LIQUID AND GAS CHROMATOGRAPHY/MASS
SPECTROMETRY (LC-QTOF-MS AND GC-QTOF-MS)
L. Pacheco Lugo1, A. Rojo Sánchez1, A. Carmona Marte1, M. Santamaría Torres2,
M. Cala Molina2, Y. Díaz Olmos1, G. Aroca Martínez1, E. Navarro Quiroz1
(1Barranquilla, CO, 2Bogotà, CO)
27STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
PO1:08 • DISTINCT TRANSCRIPTOMIC SIGNATURE OF PERIPHERAL BLOOD IN
NEUROPSYCHIATRIC LUPUS
D. Nikolopoulos1, A. Filia1, K. Katsiki1, T. Manolakou1, A. Pieta1, N. Kapsala1, A. Fanouriakis1,
D. Boumpas1, G. Bertsias2
(1Athens, GR, 2Heraklion, GR)
PO1:09 • SERUM SPHINGOLIPIDS AS A POTENTIAL BIOMARKER IN PATIENTS WITH
SYSTEMIC LUPUS ERYTHEMATOSUS
C.H. Suh1, J.W. Kim1, S.H. Kim2, S.J. Hong3
(1Suwon, KR, 2Daegu, KR, 3Seoul, KR)
PO1:10 • MULTICENTRE STUDY IN SLE PATIENTS WITH AND WITHOUT RENAL
INVOLVEMENT BY LABEL FREE PROTEOMIC ANALYSIS OF 24H URINE
N. Rivera2, E. Ruiz1, E. Galindez1, O. Fernandez1, I. Torre1, E. Cuende1, J. Blanco1,
A. Intxaurbe1, R. Exposito1, C. Garcia1, L. Vega1, M. Enjuanes1, M. García-Vivar1, M. Allande2,
J. Calvo3, E. Aurrecoechea4, L. Riancho4, A. De Diego-Sola5, M. Diaz6, F. Elortza7, I. Iloro7,
M. Azkargorta7
(1Bilbao, ES, 2Barakaldo, ES, 3Vitoria, ES, 4Torrelavega, ES, 5Donostia, ES, 6Barcelona, ES,
7
Derio, ES)
PO1:12 • TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL
MARKERS IDENTIFY TP53 AND C3AR AS DRUG TARGETS IN NEUROPSYCHIATRIC
SYSTEMIC LUPUS ERYTHEMATOSUS
J. Lindblom1, Y. Enman1, I. Parodis1, D. Toro-Domínguez2, E. Carnero-Montoro2,
M. Alarcón-Riquelme2, G. Barturen2, M.O. Borghi3, J. Castillo4, C. Mohan4, E. Iacobaeus1,
D. Repsilber5
(1Stockholm, SE, 2Granada, ES, 3Milan, IT, 4Houston, USA, 5Örebro, SE)
PO1:13 • PLASMA AND CEREBROSPINAL FLUID NEUROFILAMENT LIGHT
CONCENTRATIONS REFLECT NEURONAL DAMAGE IN SYSTEMIC LUPUS
ERYTHEMATOSUS
K.A. Zervides1, B. Gullstrand1, A.A. Bengtsson1, A. Jönsen1, S. Janelidze2, O. Hansson2,
J. Nystedt1, P. Nilsson1, P.C. Sundgren1
(1Lund, SE, 2Malmö, SE)
PO1:14 • EVALUATION OF COGNITIVE IMPAIRMENT IN SLE – A COMPARISON OF TWO
ASSESSMENT TOOLS
L. Kovács, E. Fazekas, G. Bodor, S. Burcsár, R. Hemelein, J. Kálmán, B. Rafael
(Szeged, HU)
PO1:15 • LUPUS BRAIN FOG: COGNITIVE IMPAIRMENT AND DEPRESSION IN SYSTEMIC
LUPUS ERYTHEMATOSUS
S. Fasano, L. Sadile, M. Fabrazzo, E. Di Caprio, M. Patrone, F. Riccio, A. Milone, R. Tirri, F. Ciccia
(Naples, IT)
PO1:16 • LIMBIC ENCEPHALITIS: A RARE COMPLICATION OF SYSTEMIC LUPUS
ERYTHEMATOSUS
T. Asmaa, A. Wafa, W.l. Chawad, F. Ibourk El Idrissi, H. Harmouche, M. Maamar, H. Khibri,
Z. Tazi Mezalek, M. Adnaoui
(Rabat, MA)
28STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
PO1:19 • LUPUS VASCULITIS MANIFESTING AS EIGHT-AND-A-HALF SYNDROME
M. Barguil Macêdo, J.M. Correia Monteiro, P. Vinícius da Fonseca, D. Souza Domiciano,
S. Katsuyuki Shinjo
(São Paulo, BR)
PO1:20 • PROGNOSTIC BIOMARKERS OF ORGAN DAMAGE IN PATIENTS WITH NEWLY
DIAGNOSED SLE
H. Enocsson1, C. Sjöwall1, M.L. Eloranta2, L. Rönnblom2, D. Leonard2, E. Svenungsson3,
I. Gunnarsson3, A. Jönsen4, A.A Bengtsson4
(1Linköping, SE, 2Uppsala, SE, 3Stockholm, SE, 4Lund, SE)
PO1:21 • ATTAINMENT OF EQ-5D-3L FULL HEALTH STATE AFTER THERAPY IS
ASSOCIATED WITH DECELERATED ORGAN DAMAGE ACCRUAL IN SYSTEMIC LUPUS
ERYTHEMATOSUS
J. Lindblom, S. Zetterberg, A. Borg, S. Emamikia, Y. Enman, A. Gomez, I. Parodis,
E. Heintz, M. Regardt, D. Grannas, G. von Perner
(Stockholm, SE)
PO1:22 • ONLINE EDUCATION SIGNIFICANTLY IMPROVED RHEUMATOLOGISTS’
KNOWLEDGE AND CONFIDENCE IN MINIMIZING LONG-TERM ORGAN DAMAGE IN
SLE
E. Bell1, M. Calle1, R. van Vollenhoven2
(1London, UK, 2Amsterdam, NL)
PO1:23 • THROMBOCYTOPENIA AS A PREDICTOR OF SYSTEMIC LUPUS
ERYTHEMATOSUS PROGRESSION
M. Osipyan, M. Efremidou, K. Ginosyan
(Yerevan, AM)
PO1:24 • A VASCULAR NECROSIS OF BONE IN A PATIENT WITH SYSTEMIC LUPUS
ERYTHEMATOSUS WITHOUT CORTICOSTEROID USE: A CASE REPORT
J. Noh, S. Han
(Jeju, KR)
PO1:26 • CONNECTIVE TISSUE SYSTEMIC DISEASES AND ITS ORAL HEALTH
IMPLICATIONS
B. Przywara-Chowaniec, A. Puzio, D. Blachut, L. Postek-Stefanska, B. Morawiec
(Katowice, PL)
29STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
E- POSTER SESSION 2:
ADAPTIVE IMMUNITY INCLUDING AUTOANTIBODIES, APS, DIAGNOSTIC
AND CLASSIFICATION CRITERIA
Chair: A. Tincani (Brescia, IT)
PO2:27 • EARLY CHANGES IN THE CIRCULATING B CELL COMPARTMENT ASSOCIATED
WITH RESPONSE TO TREATMENT AND OCCURRENCE OF FLARES IN PATIENTS
RECEIVING THERAPY FOR ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
M. Gatto1, A. Doria1, A. Gomez Gonzales2, J. Lindblom2, I. Parodis2,3
(1Padua, IT, 2Stockholm, SE, 3Örebro, SE)
PO2:28 • INTRACELLULAR OXIDATIVE STRESS IN T-CELLS IS ASSOCIATED WITH THE
DISEASE ACTIVITY OF LUPUS
A. Tandon, A. Sharma, A. Bhatnagar
(Chandigarh, IN)
PO2:29 • SERUM LEVELS OF B-CELL RELATED FACTORS BELONGING TO THE
TNF/TNFR SUPERFAMILY ARE LOWER IN ANTIPHOSPHOLIPID-RELATED SYNDROMES
THAN IN SYSTEMIC LUPUS ERYTHEMATOSUS
S. Piantoni1, F. Regola1, S. Bertocchi1, E. Pedretti1, S. Tamanini1, A. Tincani1, F. Franceschini1,
L. Andreoli1, T. Lowin2, G. Pongratz2
(1Brescia, IT, 2Düsseldorf, DE)
PO2:30 • IGG/IGM AUTOANTIBODY RATIOS DO NOT RELATE TO PROGRESSION
FROM INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS TO SYSTEMIC LUPUS
ERYTHEMATOSUS
S. Henning, J. Westra, V. Nedomova, B. Horvath, H. Bootsma, K. de Leeuw
(Groningen, NL)
PO2:31 • DIFFERENT PATTERNS OF LONGITUDINAL CHANGES IN ANTINUCLEAR
ANTIBODIES TITRES IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
P. Morán Álvarez, C. Bracaglia, V. Messia, I. Caiello, F. De Benedetti, E. Marasco
(Rome, IT)
PO2:32 • DISEASE ACTIVITY CORRELATION OF ANTI-DSDNA, ANTI-SM AND
ANTI-RIBO-P AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS USING THE
NOVEL PMAT TECHNOLOGY
C. Andalucia1, A. Seaman1, M.A. Aure1, M. Mahler1, A. Pérez-Isidro2, E. Ruiz-Ortiz2, O. Viñas2,
J. Ballús1, R. Ríos-Garcés1, R. Cervera1
(1San Diego, USA, 2Barcelona, ES)
PO2:33 • ASSOCIATION OF ACPA AND RF ANTIBODIES WITH SYNOVITIS AND JOINT
DESTRUCTION IN ALGERIAN PATIENTS WITH RHUPUS
S. Louahchi, A. Galleze, R. Raache, C. Touil-Boukoffa, N. Khaldoun, F. Hanni, R. Djidjik,
L. Boulgheb
(Algiers, DZ)
PO2:34 • ANTI-DNASE I ANTIBODIES: AN EMERGING DIAGNOSTIC MARKER OF SLE
A. Trofimenko, M. Mamus, E. Mozgovaya, S. Bedina, S. Spitsina
(Volgograd, RU)
30STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
PO2:35 • ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND SLE-SPECIFIC
ANTIBODIES MEASURED BY A NOVEL PMAT TECHNOLOGY IN SYSTEMIC LUPUS
ERYTHEMATOSUS
C. Andalucia1, A. Seaman1, E. Aron1, M.A. Aure1, M. Mahler1, M. López-Hoyos2, J. Irure-Ventura2,
E. González-López2, A. Roa-Bautista2
(1San Diego, USA, 2Santander, ES)
PO2:36 • CHARACTERIZATION OF PERIPHERAL BLOOD B-CELL SUBSET IN
UNTREATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
E Gerasimova, D Tabakov, T Popkova, A Avdeeva
(Moscow, RU)
PO2:37 • RISK FACTORS FOR RECURRENT THROMBOSIS AND CAUSE OF DEATH IN
PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME: A SWEDISH COHORT STUDY
N. Karandyszowska, M. Bruzelius, H. Alagündüz, J. Oesman, M. Magnusson,
E. Svenungsson, A. Antovic
(Stockholm, SE)
PO2:38 • ANTI-B2GPI-DOMAIN 1 ANTIBODIES STRATIFY HIGH RISK OF EXTRA-
CRITERIA MANIFESTATIONS IN A LARGE PROSPECTIVE CHINESE COHORT OF
ANTIPHOSPHOLIPID SYNDROME
Y. Zhou, W. Qi, J. Zhao, M. Li, X. Zeng
(Beijing, CN)
PO2:39 • LONG TERM FOLLOW UP OF PATIENTS WITH PRIMARY OBSTETRIC
ANTIPHOSPHOLIPID SYNDROME
S. Niznik1, R. Shavit1, N. Agmon-Levin1, M. Rapoport2, O. Avnery3, M. Ellis3, A. Lubetsky1
(1Ramat Gan, IL, 2Zrifin, IL, 3Kfar Saba, IL)
PO2:40 • HIGH EXPRESSION OF CD11C+TBET+ B CELL IN TRIPLE APL POSITIVE
PRIMARY OBSTETRIC ANTIPHOSPHOLIPID SYNDROME PATIENTS
Y. Long, J. Zhao, X. Tian, M. Li, X. Zeng
(Beijing, CN)
PO2:41 • CLINICAL CHARACTERISTICS OF ADVERSE PREGNANCY OUTCOME
PATIENTS WITH APL-POSITIVE IN CHINESE COHORT
Y. Long, J. Zhao, X. Tian, M. Li, X. Zeng
(Beijing, CN)
PO2:42 • THE VALUE OF IGA-ACL AND IGA-AB2-GP1 IN CLINICAL AND LABORATORY
MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS
A. Shumilova, F. Cheldieva, T. Reshetnyak, M. Cherkasova, A. Lila
(Moscow, RU)
PO2:43 • THE ACTIVITY AND DAMAGE INDEX IN SYSTEMIC LUPUS ERYTHEMATOSUS
DEPENDING ON ANTIPHOSPHOLIPID ANTIBODIES
A. Shumilova, F. Cheldieva, T. Reshetnyak, M. Cherkasova, A. Lila
(Moscow, RU)
31STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
PO2:44 • CATASTROPHIC ANTI-PHOSPHOLIPID SYNDROME AND PERIPARTUM:
A NEW OBSERVATION!
D. Hakem, N. Bouziani, A. Kella, A. Belabbas, K. Bouadjadj
(Mostaganem, DZ)
PO2:45 • AUTOANTIBODIES ASSOCIATED WITH SYSTEMIC SCLEROSIS (SSC) IN
THREE DISEASES CHARACTERIZED BY TYPE I INTERFERONS: A COMPARISON
BETWEEN SLE, PRIMARY SJÖGREN’S SYNDROME, SSC AND HEALTHY BLOOD
DONORS
R. Andraos1, P. Eriksson1, L. Wirestam1, C. Sjöwall1, A. Ahmad1, C. Dahle1, Ö. Dahlström1,
R. Hesselstrand2, K. Andréasson2
(1Linköping, SE, 2Lund, SE)
PO2:46 • CLINICAL AND IMMUNOLOGICAL CONSIDERATIONS OF CERULOPLASMIN
ACTIVITY SHIFTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
A. Trofimenko, O. Emelyanova
(Volgograd, RU)
PO2:47 • HOW SMALL DETAILS AFFECT THE SENSITIVITY OF DIFFERENT SLE
CRITERIA? INVESTIGATING A LARGE NUMBER OF PATIENTS IN A HUNGARIAN
CENTER
G. Kumánovics, D. L. Csóka, K. T. Kovács, L. Czirják
(Pécs, HU)
PO2:48 • INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL AND
IMMUNOLOGICAL MANIFESTATIONS
T. Popkova, T. Panafidina, L. Kondrateva, Y. Gorbunova, E. Nasonov, A. Lila
(Moscow, RU)
PO2:49 • PREDICTORS OF PROGRESSION IN UNDIFFERENTIATED CONNECTIVE
TISSUE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
S. Dyball1, M. Rodziewicz1, I.N. Bruce1, C. Mendoza-Pinto2, B. Parker1
(1Manchester, UK, 2Puebla, MX)
PO2:50 • UTILITY IN CLINICAL PRACTICE OF ANTI-DSDNA AUTOANTIBODIES
VS ANTI-DNA CRITHIDIA LUCILIAE IN THE DIAGNOSIS OF SYSTEMIC LUPUS
ERYTHEMATOSUS
V. Ortiz-Santamaria1, J. Camins-Fàbregas1, J. Climent-Martí2, A. Nack2, À. Prior-Español2,
L. Mateo Soria2, M. Martínez Morill2, L. Gifre2, M. Aparicio-Espinar2, A. Riveros2, C. Sangüesa2,
I. Casafont-Solé2, M. Aparicio-Rovira2, I. Peralta-Garcia2, S. Holgado2
(1Granollers, ES, 2Badalona, ES)
PO2:51 • HYPERFERRITINAEMIA AND SYSTEMIC DISEASE: SLE OR STILL’S DISEASE?
D. Hakem, A. Kella, N. Bouziani, A. Belabbas, A. Khedim
(Mostaganem, DZ)
32STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
E- POSTER SESSION 3:
CARDIOVASCULAR MANIFESTATIONS, CYTOKINES AND COMPLEMENT
SYSTEM IN SLE, DIFFICULT CASES, ORGAN DAMAGE AND SURVIVAL, INNATE
IMMUNITY
Chair: S. Jacobsen (Copenhagen, DK)
PO3:52 • PREDICTORS OF CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS
ERYTHEMATOSUS
N. Farina, J. Webster, W. Luo, D. Isenberg, A. Rahman
(London, UK)
PO3:53 • NO EVIDENCE OF A CORRELATION BETWEEN SERUM HCQ CONCENTRATIONS
AND QTC IN SLE
A. Olsson1, H. Tydén1, P. Linge1, A.A Bengtsson1, A. Jönsen1, K. Kultima2, H. Carlsson2
(1Lund, SE, 2Uppsala, SE)
PO3:54 • ASSOCIATION OF LUPUS NEPHRITIS AND ECHOCARDIOGRAPHIC
PARAMETERS
N. Guajardo-Jauregui, D.A. Galarza-Delgado, I.J. Colunga-Pedraza, J.R. Azpiri-Lopez,
J.A. Cardenas-de la Garza, S. Lugo-Perez
(Monterrey, MX)
PO3:55 • ESTIMATION OF CARDIOVASCULAR RISK AMONG SLE PATIENTS: ANALYSIS
FROM A MONOCENTRIC COHORT
R. Santangeli, G. Montozzi, L. Gamba, S. Salvucci, G. Moroncini, L. Manfredi
(Ancona, IT)
PO3:56 • ANTI-RO/SSA ANTIBODIES AND ELECTROCARDIOGRAPHIC ABNORMALITIES
IN SLE PATIENTS: PRELIMINARY DATA OF A MULTIDISCIPLINARY STUDY IN A
MONOCENTRIC COHORT
M. Fredi, S. Bertocchi, E. Pedretti, R. Rovelli, F. Franceschini, L. Serafini, A. Drera,
M. Riccardi, F. Ravasio, E. Vizzardi
(Brescia, IT)
PO3:57 • CORRELATION BETWEEN DISEASE ACTIVITY AND ECHOCARDIOGRAPHIC
PARAMETERS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
N. Guajardo-Jauregui, D.A. Galarza-Delgado, I.J. Colunga-Pedraza1, J.R. Azpiri-Lopez1,
J.A. Cardenas-de la Garza1, S. Lugo-Perez1
(Monterrey, MX)
PO3:58 • ASSOCIATION OF ANTI-DOUBLE STRANDED DNA ANTIBODY TITERS
AND ECHOCARDIOGRAPHIC PARAMETERS IN SYSTEMIC LUPUS ERYTHEMATOSUS
PATIENTS
N. Guajardo-Jauregui, I.J. Colunga-Pedraza, D.A. Galarza-Delgado, J.R. Azpiri-Lopez,
J.A. Cardenas-de la Garza, S. Lugo-Perez
(Monterrey, MX)
PO3:59 • ECHOCARDIOGRAPHIC ABNORMALITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
PATIENTS
N. Guajardo-Jauregui, I.J. Colunga-Pedraza, D.A. Galarza-Delgado, J.R. Azpiri-Lopez,
J.A. Cardenas-de la Garza, S. Lugo-Perez
(Monterrey, MX)
33STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
PO3:60 • ASSOCIATION OF LEFT VENTRICULAR GEOMETRY ABNORMALITIES AND
DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
N. Guajardo-Jauregui, J.R. Azpiri-Lopez, D.A. Galarza-Delgado, I.J. Colunga-Pedraza,
J.A. Cardenas-de la Garza, S. Lugo-Perez
(Monterrey, MX)
PO3:61 • RENAL INVOLVEMENT AND CARDIOVASCULAR RISK IN SYSTEMIC LUPUS
ERYTHEMATOSUS PATIENTS
M. De la Rubia Navarro, E. Grau Garcia, C. Pavez Perales, J.R. Ivorra Cortes, L. Gonzalez Puig,
R. Negueroles Albuixech, I. Martinez Cordellat, C. Herranz Najera, F.M. Ortiz-Sanjuan,
J. Fragio Gil, I. Canovas Olmos, E. Vicens Bernabeu, J.E. Oller Rodriguez,
S. Leal Rodriguez, C. Riesco Barcena, A.V. Huaylla Quispe, L. Mas Sanchez,
P. Muñoz Martinez, J.A. Roman Ivorra
(Valencia, ES)
PO3:62 • CARDIOPULMONARY DISEASE IN SLE - INCREASING TREND!
S. Balasubramanian, S. Nallasivan
(Madurai, IN)
PO3:64 • OPTIMISING TYPE I INTERFERON GENE EXPRESSION ASSAYS: ADDRESSING
THE RESEARCH AGENDA OF A EULAR TASK FORCE
Z. Wigston, L. Carter, A. Alase, E. Vital
(Leeds, UK)
PO3:65 • THE LEPTIN AND ADIPONECTIN LEVELS IN PATIENTS WITH SYSTEMIC
LUPUS ERYTHEMATOSUS AND THEIR RELATIONSHIP WITH CARDIOVASCULAR RISK
FACTORS
T. Popkova, L. Kondrateva, Y. Gorbunova, M. Diatroptov, T. Panafidina, E. Gerasimova
(Moscow, RU)
PO3:66 • TLR9 PROTEIN LEVEL IS ASSOCIATED TO PROINFLAMMATORY CYTOKINE
LEVEL OF IL10 AND INF1A IN SLE PATIENTS
E. Grau García1, C. Riesco Barcena1, A.V. Huaylla Quispe1, S. Leal Rodríguez1, C. Pávez
Perales1, L. Mas Sanchez1, P. Muñoz Martínez1, M. De la Rubia Navarro1, I. Cánovas Olmos1,
J. Ivorra Cortés1, J.J. Fragio Gil1, L. González Puig1, I. Martínez Cordellat1, C. Nájera Herranz1,
R. Negueroles Albuixech1, J.E. Oller Rodríguez1, F.M. Ortiz-Sanjuán1, E. Vicens Bernabéu1,
J.A. Roman Ivorra1, L. Gomez-Lechón Quirós2
(1Valencia, ES, 2Gandia, ES)
PO3:67 • MEASURING IFNA2 LEVELS BY A SINGLE-MOLECULE ARRAY IN CLINICAL
PRACTICE OF CHILDHOOD-ONSET SLE PATIENTS DOES MATTER; RESULTS FROM A
SINGLE CENTER LONGITUDINAL STUDY
M.J. Wahadat1, H.Qi1, C.G. van Helden-Meeuwsen1, E. Huijser1, L. van den Berg1, J. Göpfert2,
M. Verkaaik1, M. Schreurs1, S. Kamphuis1, M.A. Versnel1
(1Rotterdam, NL, 2Reutlingen, DE)
PO3:68 • SYSTEMIC LUPUS ERYTHEMATOSUS-RELATED INTESTINAL PSEUDO-
OBSTRUCTION TREATED WITH IMMUNOSUPPRESSANTS
I. Durucan, L. Mustafayeva, A.Y. Ayla, S. Ugurlu
(Istanbul, TR)
34STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
PO3:69 • A CASE OF LATE ONSET OF PRIMARY ANTIPHOSPHOLIPID SYNDROME
S. Salvucci, L. Manfredi, L. Gamba, G. Montozzi, R. Santangeli, G. Moroncini
(Ancona, IT)
PO3:70 • CASE REPORT OF A SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT WITH AN
ULCERATIVE NECROTIC VASCULITIS: FEATURES OF THERAPEUTIC APPROACHES
A. Shumilova, E. Naryshkin, T. Reshetnyak, E. Stolyarevich
(Moscow, RU)
PO3:71 • A UNIQUE CASE OF A DELAYED DIAGNOSIS OF STRONGYLOIDIASIS
HYPERINFECTION IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS,
LYMPHOPLASMACYTIC LYMPHOMA, AND KIDNEY INJURY
D. Bosnic, I. Aurer, S. Bulimbašic
(Zagreb, HR)
PO3:72 • EXTRACELLULAR VESICLES OPSONIZED BY MONOMERIC C-REACTIVE
PROTEIN ARE ACCESSIBLE AS AUTOANTIGENS IN SYSTEMIC LUPUS ERYTHEMATOSUS
J. Karlsson1, J. Wetterö1, C. Sjöwall1, L. Potempa2, F. Mobarrez3
(1Linköping, SE, 2Schaumburg, USA, 3Uppsala, SE)
PO3:73 • SOLUBLE CD200 CONCENTRATION IN SERUM IS INCREASED IN SLE
PATIENTS AND CORRELATES WITH ANTI-DSDNA
E. Kaan, M. Limper, M. van der Vlist
(Utrecht, NL)
35STOCKHOLM
13th EUROPEAN
LUPUS
5-8 OCTOBER
MEETING 2022
E-POSTER
E-POSTER SESSION 4:
DISEASE ACTIVITY MEASUREMENTS, FLARE AND REMISSION,
EPIDEMIOLOGY, ETIOLOGY, GENETICS, EPIGENETICS
Chair: L.P. Sousa Ines (Coimbra, PT)
PO4:75 • THE ANTI-BDCA2 ANTIBODY BIIB059 IMPROVES JOINT AND SKIN
MANIFESTATIONS IN PATIENTS WITH SLE AND BOTH ACTIVE ARTHRITIS AND RASH
R. van Vollenhoven1, R. Furie2, V.P. Werth3, H. Carroll4, X. Huang4, C. Musselli4,
N. Franchimont4, C. Barbey5, K. Kalunian6
(1Amsterdam, NL, 2New York, USA, 3Philadelphia, USA, 4Cambridge, USA, 5Baar, CH,
6
La Jolla, USA)
PO4:77 • AGREEMENT BETWEEN LLDAS AND EXPERT ASSESSMENT IN IDENTIFYING
SLE PATIENTS WITH LDA: STUDY ON A REAL-WORLD COHORT OF CAUCASIAN
PATIENTS
C. Cruciani, M. Zen, F. Arru, F. Davanzo, Z. Rahmé, R. Depascale, M. Gasparotto, M. Gatto,
L. Iaccarino, A. Doria
(Padua, IT)
PO4:78 • VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA)
SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN
RELESSER-PROS REGISTRY
L. Cáceres1, I. Rúa-Figueroa Fernández de Larrinoa1, N. Jiménez2, M. Galindo Izquierdo3,
J. Martínez Barrios3, J. Calvo Alen4, R. Menor Almagro5, A. Fernández Nebro6,
J.M. Pego Reigosa2
(1Las Palmas de Gran Canaria, ES, 2Vigo, ES, 3Madrid, ES, 4Vitoria, ES, 5Jerez, ES, 6Málaga,
ES)
PO4:79 • NAILFOLD CAPILLARY CHANGES IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOUS
S. Stefania, C. Rotondo, S. Sciacca, F.P. Cantatore, A. Corrado
(Foggia, IT)
PO4:80 • SIGNIFICANT CORRELATION BETWEEN ADJUSTED MEAN CLINICAL SLEDAI
OVER TIME AND REMISSION DEFINED BY THE DORIS CRITERIA: RESULTS FROM A
REGIONAL SWEDISH COHORT
I. Giannakou1, L. Rönnblom1, D. Leonard1, M. Frodlund2, C. Sjöwall2
(1Uppsala, SE, 2Linköping, SE)
PO4:81 • VARIABILITY OF XANTHINE OXIDOREDUCTASE ACTIVITY PATTERNS IN
SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
A. Trofimenko, E. Mozgovaya, S. Bedina, M. Mamus, S. Spitsina, I. Zborovskaya
(Volgograd, RU)
PO4:82 • CORRELATION BETWEEN ANTI DS-DNA AND SYSTEMIC LUPUS
ERYTHEMATOSUS DISEASE ACTIVITY
N. Ajasllari, M. Uruci, A. Zoto, E. Rapushi, J. Petromilo
(Tirana, AL)
36You can also read
